Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy

Choi, Hyun Chang; Kim, Jung Han; Kim, Hyeong Su; Jung, Soong Goo; Hwang, Sang Muk; Ju, Sung Bae; Yang, Ik

doi:10.7150/jca.11794



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2015; 6(7):652-657. doi:10.7150/jca.11794 This issue Cite

Research Paper

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy

Hyun Chang Choi^1*, Jung Han Kim^1*✉, Hyeong Su Kim¹, Soong Goo Jung¹, Sang Muk Hwang¹, Sung Bae Ju¹, Ik Yang²

1. Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 150-950, Republic of Korea
2. Department of Radiology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 150-950, Republic of Korea
* Hyun Chang Choi and Jung Han Kim equally contributed to this study.

Citation:

Choi HC, Kim JH, Kim HS, Jung SG, Hwang SM, Ju SB, Yang I. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. J Cancer 2015; 6(7):652-657. doi:10.7150/jca.11794. https://www.jcancer.org/v06p0652.htm

Other styles

Abstract

Background : The impact of the RECIST 1.1 on the selection of target lesions and assessment of tumor response was not evaluated in patients with advanced NSCLC who received cytotoxic chemotherapy.

Methods: We reviewed medical records of patients with advanced NSCLC who received first-line chemotherapy between January 2004 and December 2013 and compared the selection of target lesions and tumor responses using the two RECIST versions.

Results: A total of 88 patients who had at least one target lesion according to the RECIST 1.0 were included in the study. The number of target lesions by the RECIST 1.1 was significantly lower than that by the RECIST 1.0. When adopting the RECIST 1.1 instead of the RECIST 1.0, 40 patients (45.4%) showed a decrease in the number of target lesions. Three patients no longer had target lesion because of the new lymph node (LN) criteria of the RECIST 1.1. Tumor responses showed a high level of concordance between the RECIST 1.0 and RECIST 1.1, with a kappa value of 0.912. Four patients (4.5%) showed disagreement of tumor responses between the two criteria, which were all due to the change of the LN criteria.

Conclusion: The RECIST 1.1 showed a high level of concordance with the RECIST 1.0 in the assessment of tumor response in advanced NSCLC patients treated with cytotoxic chemotherapy. The new LN criteria were the major cause of the reduction of target lesions and reclassification of the tumor response.

Keywords: RECIST 1.0, RECIST 1.1, Lung cancer, Chemotherapy, Target lesion

Citation styles

APA

Choi, H.C., Kim, J.H., Kim, H.S., Jung, S.G., Hwang, S.M., Ju, S.B., Yang, I. (2015). Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. Journal of Cancer, 6(7), 652-657. https://doi.org/10.7150/jca.11794.

ACS

Choi, H.C.; Kim, J.H.; Kim, H.S.; Jung, S.G.; Hwang, S.M.; Ju, S.B.; Yang, I. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. J. Cancer 2015, 6 (7), 652-657. DOI: 10.7150/jca.11794.

NLM

CSE

Choi HC, Kim JH, Kim HS, Jung SG, Hwang SM, Ju SB, Yang I. 2015. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. J Cancer. 6(7):652-657.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.